Expression of EGFR Protein in Human Gastric Cancer and Its Clinical Value

Objective 　To investigate the expression of EGFR in gastric cancer and its relationship with clinical pathologic characters, analyze the relationship between EGFR expression and survival time of gastric cancer, and discuss the feasibility of EGFR as prognostic markers and molecular target . Methods 　The expression of EGFR in gastric cancer was studied by immunohistochemical technique with its relation to follow2up data. We analyzed its detect outcome with clinical pathologic characters. Results 　①The 44 of 103 gastric cancer specimens (42. 7 %) were positive for EGFR, and the expression of EGFR was not found in gastric normal tissue ; ②Their expression was not correlated with sex, age, size and site of tumor and degree of differentiation ( P > 0. 05) . The positive expression rates of EGFR was related to the depth of invasion, clinical stage, lymph node and distant metastasis of gastric cancer patients ( P < 0. 05) ; ③Median survival time of patients with EGFR positive is 11. 0 months. Median survival time of patient s with EGFR negative is 65. 2 months. There is statistical significe be2 tween median survival period of patients with EGFR positive and negative ( P < 0. 05) . Conclusion 　①The ex2 pression of EGFR was closely related to invasion, metastasis and prognosis of gastric cancer, and it could be used to evaluate the biological behaviors and prognosis of gastric cancer. ②High positive rate of EGFR expression in gastric cancer, provide a theoretical basis for application of molecular targeted drugs, such as IMC2C225, ZD1839 and OSI2774.